logo

Bristol-Myers Squibb Co. (BMY)



Trade BMY now with
  Date
  Headline
11/10/2017 7:03:08 AM Bristol-Myers Squibb Says Encouraging Response Observed With Opdivo (nivolumab) Plus IDO1 Inhibitor, BMS-986205
11/10/2017 6:32:09 AM Bristol-Myers : FDA Expands Approval Of Sprycel To Include Treatment Of Children With Ph+ CML In Chronic Phase
11/9/2017 8:09:01 AM Bristol-Myers Squibb And Five Prime Present Phase 1a/1b Data On Cabiralizumab With Opdivo
11/6/2017 7:16:56 AM Bristol-Myers Squibb: Opdivo Demonstrates Superior 3-yr Survival Benefit For Patients With Prior Treated Advanced RCC
10/30/2017 7:00:05 AM EMA Validates Bristol-Myers Squibb’s Type II Variation Application For Opdivo (nivolumab)
10/26/2017 7:22:23 AM Bristol-Myers Squibb Co. (BMY) Has Raised Its 2017 EPS Estimate To 2.95 - 3.05 From 2.90 - 3.00
10/26/2017 6:59:49 AM Bristol-Myers Squibb Q3 GAAP EPS $0.51 And Non-GAAP EPS $0.75
10/20/2017 7:00:26 AM Bristol-Myers Squibb To Present New Data Advancing Research Across Serious Liver Diseases At The Liver Meeting 2017